Last reviewed · How we verify
NCT04149379
Hyperbaric Oxygen Therapy After Stroke - PILOT
Phase 2 trial testing Hyperbaric oxygen in Cerebral Stroke. Withdrawn.
31 August 2021
Quick facts
| Lead sponsor | Norwegian Underwater Intervention (NUI) |
|---|---|
| Phase | Phase 2 |
| Status | Withdrawn |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Start date | 20 April 2020 |
| Primary completion | 31 August 2021 |
| Estimated completion | 20 December 2021 |
| Sites | 1 location across Norway |
Drugs / interventions tested
- Hyperbaric oxygen — full drug profile →
Conditions studied
- Cerebral Stroke — all drugs for Cerebral Stroke →
Sponsor
Norwegian Underwater Intervention (NUI)
Who can join
Adults 18 to 99, any sex, with Cerebral Stroke. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The goal of this pilot study is to establish more information about hyperbaric oxygen therapy for this group of patients, and give us more information of how to initiate the best possible main study. Can we find any indications that support the use of this therapy for patients suffering from chronic disability after cerebral infarction? Can we improve physical and cognitive function.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Detrimental Roles of Hypoxia-Inducible Factor-1α in Severe Hypoxic Brain Diseases.
Choi YK. · · 2024 · cited 23× · PMID 38674050 · DOI 10.3390/ijms25084465
Verify or expand the search:
- PubMed search for NCT04149379
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Hyperbaric oxygen
Trials testing the same drug.
- NCT06526728 — Hyperbaric Oxygen Therapy in HAMstring Injury (HOTHAM) Trial · Phase 3 · recruiting
- NCT06267300 — Treatment of Post-COVID-19 With Hyperbaric Oxygen Therapy: a Randomized, Controlled Trial · Phase 3 · unknown
- NCT05343754 — Hyperbaric Oxygen Therapy for Pyoderma Gangrenosum · Phase 3 · terminated
- NCT04862676 — Repeated HBO Therapy in Myeloma Patients Undergoing High-Dose Therapy and Auto-HCT · EARLY_PHASE1 · completed
- NCT05804097 — Does Increasing Oxygen Nurture Your Symptomatic Ischemic Ulcer Sufficiently? · Phase 4 · active not recruiting
Other recruiting trials for Cerebral Stroke
Currently open trials in the same condition.
- NCT06947343 — Effect of Action Observation Therapy in Comparison to Motor Relearning Program on Balance and Mobility Among Subacute St · NA · recruiting
- NCT06069999 — Telerehabilitation Early After CNS Injury · NA · active not recruiting
- NCT05614193 — Deep Enhanced Imaging in Stroke and Vascular Neurology · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04149379 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Norwegian Underwater Intervention (NUI)
- Last refreshed: 27 April 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04149379.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing